These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9441775)

  • 1. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.
    Luo MP; Gomperts B; Imren S; DeClerck YA; Ito M; Velicescu M; Felix JC; Dubeau L
    Gynecol Oncol; 1997 Dec; 67(3):277-84. PubMed ID: 9441775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
    Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
    Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors.
    Hirahara F; Miyagi E; Nagashima Y; Miyagi Y; Yasumitsu H; Koshikawa N; Nakatani Y; Nakazawa T; Udagawa K; Kitamura H; Minaguchi H; Miyazaki K
    Gynecol Oncol; 1998 Feb; 68(2):162-5. PubMed ID: 9514801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.
    McCluskey LL; Chen C; Delgadillo E; Felix JC; Muderspach LI; Dubeau L
    Gynecol Oncol; 1999 Jan; 72(1):87-92. PubMed ID: 9889036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activity in benign and malignant epithelial ovarian tumors.
    Wan M; Li WZ; Duggan BD; Felix JC; Zhao Y; Dubeau L
    J Natl Cancer Inst; 1997 Mar; 89(6):437-41. PubMed ID: 9091645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues.
    Baykal A; Thompson JA; Xu XC; Hahn WC; Deavers MT; Malpica A; Gershenson DM; Silva EG; Liu J
    Oncol Rep; 2004 Feb; 11(2):297-302. PubMed ID: 14719058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
    Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
    Sharma RK
    In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
    Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
    Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
    J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
    Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
    Paciucci R; Torà M; Díaz VM; Real FX
    Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells.
    Kajiyama H; Kikkawa F; Khin E; Shibata K; Ino K; Mizutani S
    Cancer Res; 2003 May; 63(9):2278-83. PubMed ID: 12727850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
    Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of BRCA1 expression in sporadic ovarian cancer.
    Zheng W; Luo F; Lu JJ; Baltayan A; Press MF; Zhang ZF; Pike MC
    Gynecol Oncol; 2000 Mar; 76(3):294-300. PubMed ID: 10684699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
    Pustilnik TB; Estrella V; Wiener JR; Mao M; Eder A; Watt MA; Bast RC; Mills GB
    Clin Cancer Res; 1999 Nov; 5(11):3704-10. PubMed ID: 10589790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.